---
layout: default
title: Ganirelix
parent: Model Prediction Only (L5)
nav_order: 312
evidence_level: L5
indication_count: 10
last_modified_at: 2026-10-15
description: "Ganirelix: predicted new indication Hypertrichosis (evidence level L5). Approved use: Prevention of premature ovulation during ovarian stimulation in ferti…"
monitor_inn: "Ganirelix"
predicted_indications: ["hypertrichosis (disease)", "Ambras type hypertrichosis universalis congenita", "malformation syndrome with odontal and/or periodontal component", "syndrome with a Dandy-Walker malformation as major feature", "isolated genetic hair shaft abnormality", "familial male-limited precocious puberty", "persistent fetal circulation syndrome", "aromatase excess syndrome", "centra precocious puberty 1", "familial isolated trichomegaly"]
---

# Ganirelix
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ganirelix: From Fertility Treatment (Ovarian Stimulation) to Hypertrichosis

## One-Sentence Summary

Ganirelix is a GnRH receptor antagonist used to prevent premature ovulation in women undergoing ovarian stimulation during fertility treatment.
The TxGNN model predicts it may be effective for **hypertrichosis**,
but there are currently **no clinical trials** and **no publications** supporting this direction, so the prediction is based on the model alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Prevention of premature ovulation during ovarian stimulation in fertility treatment (from pharmacology data; no approved indication text is recorded for the UK authorisation) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| UK Market Status | Marketed |
| Number of Marketing Authorisations | 1 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Ganirelix blocks the GnRH receptor (GNRHR) in the pituitary. This suppresses LH and FSH release and, indirectly, gonadal sex hormone production. Detailed mechanism of action data is not otherwise available in the data compiled for this report.

The only conceivable link to hypertrichosis is an indirect reduction of androgen drive. However, most forms of hypertrichosis are not androgen-dependent (they are congenital or drug-induced), so this mechanism is unlikely to apply to them. The high TxGNN score reflects proximity in a knowledge graph, not clinical or experimental support.

The other nine predictions are weaker still. Most concern congenital or structural conditions (Ambras syndrome, Dandy-Walker malformation, hair shaft abnormalities, familial trichomegaly, odontal/periodontal malformation syndromes) with no plausible link to gonadotropin signalling. Two are hormonal and deserve a brief mention as research questions only:

- **Central precocious puberty** (score 99.75%): GnRH receptor blockade is mechanistically coherent, but the standard of care is GnRH agonists. Ganirelix is short-acting with no depot form, which limits practicality.
- **Familial male-limited precocious puberty** (score 99.85%): This is driven by activating LHCGR mutations that act independently of the pituitary, so a GnRH antagonist is expected to be ineffective.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## UK Market Information

| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 0607020W0AAAAAA (BNF-style product code; PL number not available) | Ganirelix Inj 500mcg/ml 0.5ml Pfs | Pre-filled syringe (injection) | Not recorded in the data compiled for this report |

## Safety Considerations

**Drug Interactions** (7 records; six rated Moderate, one pharmacological target record):

- Gonadorelin (Moderate)
- Chorionic gonadotropin (human) (Moderate)
- Menotropins (Moderate)
- Triptorelin (Moderate)
- Follitropin (Moderate)
- Urofollitropin (Moderate)

The interactions are mainly with other gonadotropins and GnRH-related agents, which is expected given overlapping pharmacology.

Warnings and contraindications were not available. Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on a graph-based model score only, with no clinical trials or literature, and the mechanism is not plausible for most hypertrichosis forms. Evidence level is L5.

**To proceed, the following is needed:**
- Label warnings and contraindications from the SmPC/BNF (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Approved indication text for the UK authorisation, and the PL number
- Any preclinical or clinical evidence linking GnRH antagonism to hypertrichosis
- If a hormonal direction is pursued, a focused literature review on GnRH antagonists in central precocious puberty (research question only)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

